Pathogenic Th17 and Th22 Cells Are Increased in Patients with Autoimmune Thyroid Disorders

Overview

Journal Endocrine

Specialty Endocrinology

Date 2017 Jul 3

PMID 28669056

Citations 28

Authors

Marlen Vitales-Noyola

Ana M Ramos-Levi

Rebeca Martinez-Hernandez

Ana Serrano-Somavilla

Miguel Sampedro-Nunez

Roberto Gonzalez-Amaro

Monica Marazuela

Affiliations

Soon will be listed here.

Abstract

Purpose: To study the levels of pathogenic and non-pathogenic Th17 and Th22 cells in autoimmune thyroid disorders patients. Although Th17 cells seem to play an important role in the pathogenesis of thyroid autoimmune disorders, the specific subsets of these lymphocytes have not been analyzed in this condition.

Methods: We assessed the levels of Th17 (pathogenic and non-pathogenic) and Th22 cells in peripheral blood and thyroid glands of autoimmune thyroid disorders patients (n = 26, 16 with Graves' disease and 10 with Hashimoto's thyroiditis) and 15 healthy controls by multi-parametric flow cytometry and immunofluorescence microscopy.

Results: We found increased levels of pathogenic Th17 lymphocytes and Th22 cells in peripheral blood from autoimmune thyroid disorders patients. In addition, these cells were detected in thyroid glands from HT patients. Furthermore, we found significant correlations between the levels of these cells and disease activity, disease duration, and the presence of ophthalmopathy.

Conclusions: The increased levels of pathogenic Th17 lymphocytes and Th22 cells in autoimmune thyroid disorders suggest their involvement in the pathogenesis of this condition.

Citing Articles

Effect of methimazole treatment on Th1, Th17, and Th22 lymphocytes in pediatric Graves' disease patients.

Starosz A, Stozek K, Opechowska A, Bossowski F, Moniuszko M, Grubczak K Front Immunol. 2024; 15:1431686.

PMID: 39439793 PMC: 11494814. DOI: 10.3389/fimmu.2024.1431686.

Monozygotic triplets with juvenile-onset autoimmunity and 18p microdeletion involving .

Herlin M, Jensen J, Andreasen L, Petersen M, Lonskov J, Thorup M Front Genet. 2024; 15:1437566.

PMID: 39359478 PMC: 11445036. DOI: 10.3389/fgene.2024.1437566.

The phenotypic characteristics of polymorphonuclear neutrophils and their correlation with B cell and CD4+T cell subsets in thyroid-associated ophthalmopathy.

Jin K, Yao Q, Sun B Front Immunol. 2024; 15:1413849.

PMID: 39234250 PMC: 11371595. DOI: 10.3389/fimmu.2024.1413849.

Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution.

Martinez-Hernandez R, Sanchez de la Blanca N, Sacristan-Gomez P, Serrano-Somavilla A, de Nova J, Sanchez Cabo F Nat Commun. 2024; 15(1):5895.

PMID: 39003267 PMC: 11246508. DOI: 10.1038/s41467-024-50192-5.

The Role of the Immune System in the Course of Hashimoto's Thyroiditis: The Current State of Knowledge.

Wronska K, Halasa M, Szczuko M Int J Mol Sci. 2024; 25(13).

PMID: 38999993 PMC: 11241408. DOI: 10.3390/ijms25136883.

References

Ruggeri R, Saitta S, Cristani M, Giovinazzo S, Tigano V, Trimarchi F . Serum interleukin-23 (IL-23) is increased in Hashimoto's thyroiditis. Endocr J. 2014; 61(4):359-63. DOI: 10.1507/endocrj.ej13-0484. View

Antonelli A, Ferrari S, Corrado A, Di Domenicantonio A, Fallahi P . Autoimmune thyroid disorders. Autoimmun Rev. 2014; 14(2):174-80. DOI: 10.1016/j.autrev.2014.10.016. View

Li J, Hong F, Zeng J, Huang G . Functional interleukin-17 receptor A are present in the thyroid gland in intractable Graves disease. Cell Immunol. 2013; 281(1):85-90. DOI: 10.1016/j.cellimm.2013.02.002. View

Santaguida M, Gatto I, Mangino G, Virili C, Stramazzo I, Fallahi P . BREG cells in Hashimoto's thyroiditis isolated or associated to further organ-specific autoimmune diseases. Clin Immunol. 2017; 184:42-47. DOI: 10.1016/j.clim.2017.04.012. View

Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S . Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009; 119(12):3573-85. PMC: 2786807. DOI: 10.1172/JCI40202. View

Hueber W, Sands B, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins P . Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61(12):1693-700. PMC: 4902107. DOI: 10.1136/gutjnl-2011-301668. View

Gonzalez-Amaro R, Marazuela M . T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity. Endocrine. 2015; 52(1):30-8. DOI: 10.1007/s12020-015-0759-7. View

Basdeo S, Moran B, Cluxton D, Canavan M, McCormick J, Connolly M . Polyfunctional, Pathogenic CD161+ Th17 Lineage Cells Are Resistant to Regulatory T Cell-Mediated Suppression in the Context of Autoimmunity. J Immunol. 2015; 195(2):528-40. DOI: 10.4049/jimmunol.1402990. View

Mao C, Wang S, Xiao Y, Xu J, Jiang Q, Jin M . Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. J Immunol. 2011; 186(8):4734-43. DOI: 10.4049/jimmunol.0904135. View

10.

Figueroa-Vega N, Sanz-Cameno P, Moreno-Otero R, Sanchez-Madrid F, Gonzalez-Amaro R, Marazuela M . Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features. J Clin Endocrinol Metab. 2009; 94(4):1145-53. DOI: 10.1210/jc.2008-1571. View

11.

Wei H, Guan M, Qin Y, Xie C, Fu X, Gao F . Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy. Endocr J. 2014; 61(11):1087-92. DOI: 10.1507/endocrj.ej14-0246. View

12.

Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C . Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008; 158(3):273-85. DOI: 10.1530/EJE-07-0666. View

13.

Ramos-Levi A, Marazuela M . Pathogenesis of thyroid autoimmune disease: the role of cellular mechanisms. Endocrinol Nutr. 2016; 63(8):421-9. DOI: 10.1016/j.endonu.2016.04.003. View

14.

Li D, Cai W, Gu R, Zhang Y, Zhang H, Tang K . Th17 cell plays a role in the pathogenesis of Hashimoto's thyroiditis in patients. Clin Immunol. 2013; 149(3):411-20. DOI: 10.1016/j.clim.2013.10.001. View

15.

Langrish C, Chen Y, Blumenschein W, Mattson J, Basham B, Sedgwick J . IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 201(2):233-40. PMC: 2212798. DOI: 10.1084/jem.20041257. View

16.

Witte E, Witte K, Warszawska K, Sabat R, Wolk K . Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev. 2010; 21(5):365-79. DOI: 10.1016/j.cytogfr.2010.08.002. View

17.

Song X, Gao H, Qian Y . Th17 differentiation and their pro-inflammation function. Adv Exp Med Biol. 2014; 841:99-151. DOI: 10.1007/978-94-017-9487-9_5. View

18.

Kim S, Yoon J, Kim K, Lee S . Increased serum interleukin-17 in Graves' ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2012; 250(10):1521-6. DOI: 10.1007/s00417-012-2092-7. View

19.

Ruggeri R, Minciullo P, Saitta S, Giovinazzo S, Certo R, Campenni A . Serum interleukin-22 (IL-22) is increased in the early stage of Hashimoto's thyroiditis compared to non-autoimmune thyroid disease and healthy controls. Hormones (Athens). 2014; 13(3):338-44. DOI: 10.14310/horm.2002.1483. View

20.

Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y . Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature. 2013; 496(7446):513-7. PMC: 3637879. DOI: 10.1038/nature11984. View